mRNA疫苗接种与美国必要及一线工作人员COVID-19临床和病毒学特征的关联
该前瞻性队列研究纳入2020年12月14日至2022年4月19日期间美国六州1199例经逆转录聚合酶链反应确诊的SARS-CoV-2感染者,评估2或3剂mRNA疫苗接种与症状及病毒RNA载量的关联。结果显示,在Delta或Omicron变异株感染前150天内接种疫苗,部分比较中与症状减轻、病程缩短、就医减少或病毒载量降低相关,但特定估计的精确度和统计学显著性存在差异。
要点
- Delta感染前14-149天接种第二剂者较未接种者症状风险显著降低(OR 0.13)。
- Omicron感染前7-149天接种第三剂者较未接种者发热寒战风险显著降低(OR 0.25)。
- Omicron感染中三剂接种者较未接种者症状感染风险显著升高(OR 2.0)。
核心结论
- 在美国必要及一线工作人员队列中,感染Delta或Omicron变异株前不足150天接种2或3剂mRNA疫苗,与未接种相比,部分比较中与症状减轻、病程缩短、就医减少或病毒载量降低相关,但特定估计的精确度和统计学显著性存在差异。
研究设计与样本
- 前瞻性队列研究,纳入亚利桑那、佛罗里达、明尼苏达、俄勒冈、德克萨斯和犹他州经逆转录聚合酶链反应确诊的COVID-19感染者。
- 分析纳入2020年12月14日至2022年4月19日期间1199例SARS-CoV-2感染者,随访报告至2022年5月9日。
- 暴露为SARS-CoV-2谱系(原始株、Delta变异株、Omicron变异株)和COVID-19疫苗接种状态。
- 标本通过每周自采及COVID-19症状出现时自采,谱系经全基因组测序分类。
主要发现
- 1199例感染者中位年龄41岁,714例(59.5%)为女性;14.0%感染原始株,24.0%感染Delta变异株,62.0%感染Omicron变异株。
- Delta感染前14-149天接种第二剂者较未接种者症状风险显著降低(21/27[77.8%] vs 74/77[96.1%];OR 0.13[95%CI 0-0.6])。
- Delta感染前7-149天接种第三剂且有症状者较未接种者有症状者发热寒战风险显著降低(5/13[38.5%] vs 62/73[84.9%];OR 0.07[95%CI 0.0-0.3]),症状天数显著更少(10.2 vs 16.4;差值-6.1[95%CI -11.8至-0.4]天)。
- Omicron感染中,2剂接种状态较未接种状态有症状感染风险无显著差异;3剂接种者较未接种者有症状感染风险显著更高(327/370[88.4%] vs 85/107[79.4%];OR 2.0[95%CI 1.1-3.5])。
- 有症状Omicron感染中,感染前7-149天接种第三剂者较未接种者发热寒战风险显著降低(160/311[51.5%] vs 64/81[79.0%];OR 0.25[95%CI 0.1-0.5]),就医风险显著降低(45/308[14.6%] vs 20/81[24.7%];OR 0.45[95%CI 0.2-0.9])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 特定估计的精确度和统计学显著性存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Data on the epidemiology of mild to moderately severe COVID-19 are needed to inform public health guidance. OBJECTIVE: To evaluate associations between 2 or 3 doses of mRNA COVID-19 vaccine and attenuation of symptoms and viral RNA load across SARS-CoV-2 viral lineages. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study of essential and frontline workers in Arizona, Florida, Minnesota, Oregon, Texas, and Utah with COVID-19 infection confirmed by reverse transcriptase-polymerase chain reaction testing and lineage classified by whole genome sequencing of specimens self-collected weekly and at COVID-19 illness symptom onset. This analysis was conducted among 1199 participants with SARS-CoV-2 from December 14, 2020, to April 19, 2022, with follow-up until May 9, 2022, reported. EXPOSURES: SARS-CoV-2 lineage (origin strain, Delta variant, Omicron variant) and COVID-19 vaccination status. MAIN OUTCOMES AND MEASURES: Clinical outcomes included presence of symptoms, specific symptoms (including fever or chills), illness duration, and medical care seeking. Virologic outcomes included viral load by quantitative reverse transcriptase-polymerase chain reaction testing along with viral viability. RESULTS: Among 1199 participants with COVID-19 infection (714 [59.5%] women; median age, 41 years), 14.0% were infected with the origin strain, 24.0% with the Delta variant, and 62.0% with the Omicron variant. Participants vaccinated with the second vaccine dose 14 to 149 days before Delta infection were significantly less likely to be symptomatic compared with unvaccinated participants (21/27 [77.8%] vs 74/77 [96.1%]; OR, 0.13 [95% CI, 0-0.6]) and, when symptomatic, those vaccinated with the third dose 7 to 149 days before infection were significantly less likely to report fever or chills (5/13 [38.5%] vs 62/73 [84.9%]; OR, 0.07 [95% CI, 0.0-0.3]) and reported significantly fewer days of symptoms (10.2 vs 16.4; difference, -6.1 [95% CI, -11.8 to -0.4] days). Among those with Omicron infection, the risk of symptomatic infection did not differ significantly for the 2-dose vaccination status vs unvaccinated status and was significantly higher for the 3-dose recipients vs those who were unvaccinated (327/370 [88.4%] vs 85/107 [79.4%]; OR, 2.0 [95% CI, 1.1-3.5]). Among symptomatic Omicron infections, those vaccinated with the third dose 7 to 149 days before infection compared with those who were unvaccinated were significantly less likely to report fever or chills (160/311 [51.5%] vs 64/81 [79.0%]; OR, 0.25 [95% CI, 0.1-0.5]) or seek medical care (45/308 [14.6%] vs 20/81 [24.7%]; OR, 0.45 [95% CI, 0.2-0.9]). Participants with Delta and Omicron infections who received the second dose 14 to 149 days before infection had a significantly lower mean viral load compared with unvaccinated participants (3 vs 4.1 log10 copies/μL; difference, -1.0 [95% CI, -1.7 to -0.2] for Delta and 2.8 vs 3.5 log10 copies/μL, difference, -1.0 [95% CI, -1.7 to -0.3] for Omicron). CONCLUSIONS AND RELEVANCE: In a cohort of US essential and frontline workers with SARS-CoV-2 infections, recent vaccination with 2 or 3 mRNA vaccine doses less than 150 days before infection with Delta or Omicron variants, compared with being unvaccinated, was associated with attenuated symptoms, duration of illness, medical care seeking, or viral load for some comparisons, although the precision and statistical significance of specific estimates varied.
引用
- Thompson MG, Yoon SK, Naleway AL, et al. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. JAMA. 2022. PMID: 36255426. doi:10.1001/jama.2022.18550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。